Pfizer (PFE) Revenue — Quarter Ended Sep 29, 2024
Revenue for the current quarter rose sharply compared to both the prior quarter and the same period last year. The increase was driven by strong contributions from key products including an antiviral treatment, recently acquired oncology assets, and a cardiovascular therapy, partly offset by lower sales of certain legacy products.
Key takeaway
Quarter ended Sep 29, 2024 · FY2024 Q3
Revenue for the current quarter rose sharply compared to both the prior quarter and the same period last year. The increase was driven by strong contributions from key products including an antiviral treatment, recently acquired oncology assets, and a cardiovascular therapy, partly offset by lower sales of certain legacy products.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$17.7B
Revenue reported for this quarter.
Quarter-over-quarter
+33.3%
Change from the immediately preceding quarter.
Year-over-year
+31.2%
Change from the comparable year-ago quarter.
Trailing four quarters
$60.4B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2023 | $14.6B | -42.0% |
| Mar 31, 2024 | $14.9B | -19.5% |
| Jun 30, 2024 | $13.3B | +2.1% |
| Sep 29, 2024 | $17.7B | +31.2% |
Revenue performance
The quarter's revenue growth was supported by higher sales of the antiviral treatment and the addition of products from the recent acquisition, as well as continued momentum in the cardiovascular portfolio. These gains more than offset declines in two mature products.
Quarterly comparison
Compared with the immediately preceding quarter, revenue increased significantly, reversing the prior quarter's subdued trend. On a year-over-year basis, revenue also posted a strong gain, outperforming the performance of earlier quarters in the fiscal year.
What to watch
Monitor whether the expected revenue seasonality, with a heavy weighting toward the fourth quarter, leads to a further sequential increase.